ARID1B is a specific vulnerability in ARID1A-mutant cancers
Open Access
- 23 February 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 20 (3), 251-254
- https://doi.org/10.1038/nm.3480
Abstract
Mutations inactivating ARID1A, a subunit of the chromatin remodeling SWI/SNF complex, have been identified in some human cancers. This study reveals that cancer cells with mutated ARID1A are dependent on the residual activity of the complex for proliferation and that even if concomitant alterations in the ARID1A homolog ARID1B can occur, loss of ARID1B activity confers a specific vulnerability to ARID1A-mutant cells that may in the future be explored for targeting purposes. Recent studies have revealed that ARID1A, encoding AT-rich interactive domain 1A (SWI-like), is frequently mutated across a variety of human cancers and also has bona fide tumor suppressor properties. Consequently, identification of vulnerabilities conferred by ARID1A mutation would have major relevance for human cancer. Here, using a broad screening approach, we identify ARID1B, an ARID1A homolog whose gene product is mutually exclusive with ARID1A in SWI/SNF complexes, as the number 1 gene preferentially required for the survival of ARID1A-mutant cancer cell lines. We show that loss of ARID1B in ARID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation in both cancer cells and primary cells. We also find that ARID1A and ARID1B are frequently co-mutated in cancer but that ARID1A-deficient cancers retain at least one functional ARID1B allele. These results suggest that loss of ARID1A and ARID1B alleles cooperatively promotes cancer formation but also results in a unique functional dependence. The results further identify ARID1B as a potential therapeutic target for ARID1A-mutant cancers.Keywords
This publication has 27 references indexed in Scilit:
- A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1Cancer Research, 2013
- Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promotersProceedings of the National Academy of Sciences of the United States of America, 2013
- Punctuated Evolution of Prostate Cancer GenomesCell, 2013
- Selective inhibition of BET bromodomainsNature, 2010
- Mammalian SWI/SNF-A Subunit BAF250/ARID1 Is an E3 Ubiquitin Ligase That Targets Histone H2BMolecular and Cellular Biology, 2010
- Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling ComplexCancer Research, 2009
- ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250aProceedings of the National Academy of Sciences, 2008
- Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformationProceedings of the National Academy of Sciences, 2005
- The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiationThe EMBO Journal, 2005
- An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 2005